Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C48H74O14 |
Molecular Weight | 875.0928 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 20 / 20 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]6([H])C[C@@H](C[C@]7(CC[C@H](C)[C@]([H])(O7)[C@@H](C)CC)O6)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O
InChI
InChIKey=AZSNMRSAGSSBNP-XPNPUAGNSA-N
InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
Molecular Formula | C48H74O14 |
Molecular Weight | 875.0928 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 20 / 20 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://biolinks.co.jp/pdf/Ivermectin.pdfCurator's Comment: description was created based on several sources, including:
http://evans.rc.fas.harvard.edu/pdf/smnr_2000-2001_Raymer_Brian.pdf | http://www.inchem.org/documents/pims/pharm/ivermect.htm
Sources: http://biolinks.co.jp/pdf/Ivermectin.pdf
Curator's Comment: description was created based on several sources, including:
http://evans.rc.fas.harvard.edu/pdf/smnr_2000-2001_Raymer_Brian.pdf | http://www.inchem.org/documents/pims/pharm/ivermect.htm
22,23-dihydro-avermectin B1a is a major form of Ivermectin mixture (more than 90%). It is a broad-spectrum anthelmintic (worms), microfilaricide (heartworms), and miticide (mites) drug, used for horses, cattle, pigs, household pets. Ivermectin used in humans, especially for river blindness. Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/464561
Curator's Comment: http://biolinks.co.jp/pdf/Ivermectin.pdf
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Glutamate-gated chloride ion channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/25987225 |
0.35 nM [Kd] | ||
Target ID: CHEMBL2094121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11082440 |
33.0 nM [IC50] | ||
Target ID: CHEMBL3392921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11082440 |
156.0 nM [IC50] | ||
Target ID: CHEMBL2492 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9463487 |
9.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | STROMECTOL Approved UseSTROMECTOL is indicated for the treatment of the following infections:
Strongyloidiasis of the intestinal tract. STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis.
Onchocerciasis. STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus. Launch Date1998 |
PubMed
Title | Date | PubMed |
---|---|---|
Development and validation of a new HPLC-UV method for the simultaneous determination of triclabendazole and ivermectin B1a in a pharmaceutical formulation. | 2010 Nov-Dec |
|
Synthesis of photoreactive ivermectin B1a derivatives and their actions on Haemonchus and Bombyx glutamate-gated chloride channels. | 2015 May |
|
Designed biosynthesis of 25-methyl and 25-ethyl ivermectin with enhanced insecticidal activity by domain swap of avermectin polyketide synthase. | 2015 Sep 24 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20059830
2 mg/mL (1 ml/ 10 Kg body weight)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9463487
The effects of ivermectin B1a (IVM)on K-28 cells expressing the human a7 nAChR was assessed. The application of IVM alone
induced no detectable current in every cell tested (n=15). Preapplication of 25 mM IVM elicited a significant increase in the current evoked by low ACh concentration (30 mM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:42:26 GMT 2023
by
admin
on
Fri Dec 15 15:42:26 GMT 2023
|
Record UNII |
91Y2202OUW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
63941
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY | |||
|
C052102
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200633
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY | |||
|
m6566
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
6321424
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY | |||
|
91Y2202OUW
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY | |||
|
DTXSID8023181
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY | |||
|
71827-03-7
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY | |||
|
276-046-2
Created by
admin on Fri Dec 15 15:42:26 GMT 2023 , Edited by admin on Fri Dec 15 15:42:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |